Screener
Allogene Therapeutics ALLO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(42,607) | $(59,733) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 8,270 | 12,175 |
| Depreciation and amortization | 2,869 | 3,099 |
| Net amortization/accretion on investment securities | (885) | (1,306) |
| Non-cash rent expense | 1,069 | 1,130 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's stock-based comp?
- Allogene Therapeutics (ALLO) reported stock-based comp of $8.27M in Q1 2026.
- How has Allogene Therapeutics's stock-based comp changed year-over-year?
- Allogene Therapeutics's stock-based comp decreased by 32.1% year-over-year, from $12.18M to $8.27M.
- What is the long-term trend for Allogene Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Allogene Therapeutics's stock-based comp has grown at a -17.4% compound annual growth rate (CAGR), from $80.82M to $37.64M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Allogene Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude